{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:30:30Z","timestamp":1791084630856,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002550"],"award-info":[{"award-number":["UL1TR002550"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jaip.2021.09.030","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T14:32:10Z","timestamp":1632839530000},"page":"478-484.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1660-6448","authenticated-orcid":false,"given":"Hannah","family":"Wangberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha R.","family":"Spierling Bagsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilliana","family":"Osuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.09.030_bib1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.030_bib2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.09.030_bib3","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaci.2020.10.043","volume":"147","author":"Stevens","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.030_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/0194599816640723","article-title":"The role of surgery in management of Samter\u2019s triad: a systematic review","volume":"155","author":"Adelman","year":"2016","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaip.2021.09.030_bib5","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jaip.2019.02.037","article-title":"Sinus surgery improves lower respiratory tract reactivity during aspirin desensitization for AERD","volume":"7","author":"Huang","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.09.030_bib6","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1136\/thorax.55.suppl_2.S87","article-title":"Surgical treatment of nasal polyposis in patients with aspirin intolerance","volume":"55","author":"Hosemann","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2021.09.030_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1385\/CRIAI:24:2:159","article-title":"Aspirin desensitization in patients with AERD","volume":"24","author":"Stevenson","year":"2003","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.09.030_bib8","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/alr.22428","article-title":"Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis","volume":"9","author":"Chu","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2021.09.030_bib9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/1945892418770260","article-title":"Long-term clinical outcomes of aspirin desensitization with continuous daily aspirin therapy in aspirin-exacerbated respiratory disease","volume":"32","author":"Walters","year":"2018","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2021.09.030_bib10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1067\/mai.2003.7","article-title":"Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease","volume":"111","author":"Berges-Gimeno","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.030_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2500\/aap.2011.32.3437","article-title":"Side effects from daily aspirin treatment in patients with AERD: identification and management","volume":"32","author":"White","year":"2011","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2021.09.030_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.anai.2019.10.016","article-title":"Asthma biologics: comparing trial designs, patient cohorts and study results","volume":"124","author":"Doroudchi","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.09.030_bib13","series-title":"FDA approves first treatment for chronic rhinosinusitis with nasal polyps [press release]","year":"2019"},{"key":"10.1016\/j.jaip.2021.09.030_bib14","series-title":"Novartis receives EC approval for new Xolair\u00ae indication to treat severe chronic rhinosinusitis with nasal polyps [press release]","year":"2020"},{"key":"10.1016\/j.jaip.2021.09.030_bib15","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.jaip.2019.03.023","article-title":"Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma","volume":"7","author":"Bachert","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.09.030_bib16","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.030_bib17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.030_bib18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jaci.2020.01.020","article-title":"Biologics for chronic rhinosinusitis with nasal polyps","volume":"145","author":"Bachert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.030_bib19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2021.09.030_bib20","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.09.030_bib21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2500\/aap.2019.40.4241","article-title":"Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease","volume":"40","author":"Jean","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2021.09.030_bib22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/1945892420972326","article-title":"Effects of omalizumab treatment in patients with recalcitrant nasal polyposis and mild asthma: a multicenter retrospective study","volume":"35","author":"Armengot-Carceller","year":"2021","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2021.09.030_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1945892420961969","article-title":"Dupilumab as add-on therapy for chronic rhinosinusitis with nasal polyposis in aspirin exacerbated respiratory disease","volume":"35","author":"Mustafa","year":"2021","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2021.09.030_bib24","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2021.09.030_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13223-020-00423-3","article-title":"Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report","volume":"16","author":"Caruso","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.030_bib26","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.09.030_bib27","series-title":"FDA approves Dupixent (dupilumab) for moderate-to-severe asthma [press release]","year":"2018"},{"key":"10.1016\/j.jaip.2021.09.030_bib28","first-page":"CD013513","article-title":"Biologics for chronic rhinosinusitis","volume":"3","author":"Chong","year":"2021","journal-title":"Cochrane Database Syst Rev"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821010564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821010564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:32:25Z","timestamp":1761975145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821010564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2213219821010564"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.09.030","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}